ATE244891T1 - Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope - Google Patents

Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Info

Publication number
ATE244891T1
ATE244891T1 AT97919749T AT97919749T ATE244891T1 AT E244891 T1 ATE244891 T1 AT E244891T1 AT 97919749 T AT97919749 T AT 97919749T AT 97919749 T AT97919749 T AT 97919749T AT E244891 T1 ATE244891 T1 AT E244891T1
Authority
AT
Austria
Prior art keywords
vaccines
epitopes
cell
present
selection
Prior art date
Application number
AT97919749T
Other languages
English (en)
Inventor
Der Burg Sjoerd Henricus Van
Wybe Martin Kast
Reinaldus Everardus Maria Toes
Rienk Offringa
Cornelius Johannes Mari Melief
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE244891T1 publication Critical patent/ATE244891T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97919749T 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope ATE244891T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96203670 1996-12-23
PCT/NL1997/000229 WO1997041440A1 (en) 1996-04-26 1997-04-28 Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes

Publications (1)

Publication Number Publication Date
ATE244891T1 true ATE244891T1 (de) 2003-07-15

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919749T ATE244891T1 (de) 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Country Status (11)

Country Link
US (1) US20070025968A1 (de)
EP (1) EP0900380B1 (de)
JP (1) JP4108126B2 (de)
AT (1) ATE244891T1 (de)
AU (1) AU738649B2 (de)
CA (1) CA2252675A1 (de)
DE (1) DE69723434T2 (de)
DK (1) DK0900380T3 (de)
ES (1) ES2205209T3 (de)
PT (1) PT900380E (de)
WO (1) WO1997041440A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
EP1012173B1 (de) * 1997-06-23 2007-10-31 Ludwig Institute For Cancer Research Isolierte decapeptide, die an hla moleküle binden, sowie deren verwendung
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
WO1999061065A1 (en) * 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
ES2326146T3 (es) * 1998-06-17 2009-10-01 Idm Pharma, Inc. Peptidos de union a hla y sus usos.
AU5776799A (en) 1998-08-21 2000-03-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modified hcv peptide vaccines
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP2177534A3 (de) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroklitische Analoga von Klasse-i Epitopen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AU780064B2 (en) * 1999-12-28 2005-02-24 Epimmune, Inc. Optimized minigenes and peptides encoded thereby
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
EP1363938B1 (de) 2000-08-03 2013-12-11 Johns Hopkins University An endoplasmatischen reticulums chaperonprotein gebundenes antigen als molekulärimpfstoff
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
JP2004517609A (ja) * 2000-09-01 2004-06-17 エピミューン インコーポレイテッド Hla−a2.1結合ペプチドおよびそれらの用途
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
BR0209854A (pt) * 2001-05-18 2004-06-08 Powderject Vaccines Inc Molécula de ácido nucléico recombinante, cassete de expressão, vetor, polipeptìdeo, composição de vacina, dispositivo de aceleração de partìcula, e, método para gerar uma resposta imune celular em um indivìduo
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
EP1644048B1 (de) 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Hla−a24拘束性腫瘍抗原ペプチド
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (de) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogene Streptokokkus-Proteine
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JPWO2019054409A1 (ja) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Hlaタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU7958994A (en) * 1993-10-05 1995-05-01 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
US20070025968A1 (en) 2007-02-01
EP0900380A1 (de) 1999-03-10
AU738649B2 (en) 2001-09-20
EP0900380B1 (de) 2003-07-09
DK0900380T3 (da) 2003-11-03
CA2252675A1 (en) 1997-11-06
PT900380E (pt) 2003-12-31
DE69723434T2 (de) 2004-05-19
DE69723434D1 (de) 2003-08-14
ES2205209T3 (es) 2004-05-01
AU2410697A (en) 1997-11-19
JP4108126B2 (ja) 2008-06-25
WO1997041440A1 (en) 1997-11-06
JP2000510689A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
CN111440229B (zh) 新型冠状病毒t细胞表位及其应用
EP0752886B1 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
Lachmann et al. Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals
CA2290485A1 (en) Method for the production of non-immunogenic proteins
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
EP1616876A3 (de) Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
AU7752487A (en) Immunomodulating compositions and their use
DE69716240D1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE60229659D1 (de) Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
AU707083B2 (en) Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
Salabert et al. Intradermal injection of an anti‐Langerin‐HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo
Bittner‐Eddy et al. Identification of gingipain‐specific I‐A b‐restricted CD 4+ T cells following mucosal colonization with P orphyromonas gingivalis in C 57 BL/6 mice
EP0753009A1 (de) Malariapeptide
GB8912651D0 (en) Peptide fragments of hiv
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
EP0656010B8 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties